UK healthtech company unveils cancer testing strategy for women

The UK healthtech company EDX Medical Group has announced plans to prioritise testing products for cancer affecting women.

Founded by Professor Sir Christopher Evans, the London-based company specialises in cancer treatments and diagnostics.

EDX Medical aims to develop and validate digitally-enabled diagnostic products and services to help predict disease risk, inform clinical decision-making and accelerate the development of new medicines in the areas of cancer, heart disease, neurology and infectious diseases.

According to CancerResearch UK, breast cancer is the most common cancer in UK females, accounting for almost a third (30 per cent) of all female cases. The next most common cancers in UK females are lung cancer (13 per cent) and bowel cancer (10 per cent).

Together breast, lung and bowel cancers account for over half (54 per cent) of all new cases in women in the UK.

“We are driving biomedical and digital innovation in cancer testing at a time when the need for greater access to risk assessment, diagnosis and personalised treatment of cancer has never been greater,” said Dr Mike Hudson, the company’s CEO.

“A key focus of our work is the expansion of advanced tests for cancers affecting women. Early disease detection and risk prediction is the most impactful way of reducing deaths and lowering the future costs of healthcare provision globally.”

Jason Holt, chairman of EDX Medical Group, said: “We are proud to be bringing EDX Medical to the AQSE Growth Market today as an important part of our strategy to develop a substantial digital healthcare business.

“Initially, we are focusing on cancer testing and are building on the expertise and experience of our founder and leadership team particularly in relation to the utilisation of advanced molecular and genomic testing to improve the detection and treatment of cancer.”

EDX Medical operates a molecular biology and diagnostics laboratory in Cambridge from which it performs research and development (R&D) and provides testing and genomic sequencing services.

Key tests performed in this laboratory have been audited by the United Kingdom Accreditation Service (UKAS) and accredited to the International Organization for Standardization.